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Probable association 
of neonatal death with 
the use of tramadol to treat 
labour pain
ABSTRACT
Tramadol is often used in obstetrics for the relief of labour pain. It has a dual mechanism of action, a monoaminergic effect 
of tramadol itself and an opioid effect, primarily mediated by its metabolite O-desmethyl tramadol, formed by genetically 
polymorphic cytochrome P450 2D6. In newborns, elimination of O-desmethyl tramadol is prolonged due to immature 
renal function. We report on a case of neonatal death following rectal administration of tramadol to treat labour pain to a 
birth-giving mother. An objective causality assessment using the Naranjo probability scale revealed that the likelihood of 
tramadol causing respiratory depression was probable. We hypothesize that neonatal death was associated with an incre-
ased exposure to O-desmethyl tramadol due to ultrarapid metabolizer cytochrome P450 2D6 genotype of the mother. More 
evidence is needed to support this association. Nevertheless, in obstetric analgesia, tramadol should be used with more 
caution until more safety data are available. 
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Introduction
Tramadol is a centrally acting analge-
sic. In humans it is extensively meta-
bolized, with major metabolites being 
O-desmethyl (M1) and N-desmethyl 
(M2) tramadol. Both, tramadol and its 
metabolite M1 are agonists of the  opi-
oid receptor. Compared to parent tra-
madol, M1 has approximately 700 fold 
higher affinity for the -receptors. (1) 
Consequently, M1 metabolite is predo-
minantly responsible for the -receptor 
mediated analgesic effect of tramadol, 
although nonopioid mechanisms of 
action potentiate opioid effects. (2) The 
dual mode of action of tramadol by 
inhibition of noradrenaline and seroto-
nin reuptake, besides agonism at the 
opioid receptors, causes decreased 
risk of respiratory depression. (3,4) In 
obstetrics it is used to treat labour pain. 
(5) It was demonstrated that tramadol 
(50-100 mg) in the first stage of labour 
is as effective as pethidine (50-75 mg), 
but has a superior safety profile. (6) 
In vitro it was demonstrated that for-
mation of M1 is catalyzed by the liver 
enzyme cytochrome P450 (CYP) 2D6. 
(7) The gene encoding for CYP2D6 is 
polymorphic resulting in functionally dif-
ferent enzymes, characterized in poor 
(PM), intermediate (IM), extensive (EM) 
and ultrarapid (UM) metabolizer phe-
notypes. Tramadol and M1 pass the 
placental barrier. (8) Depending on the 
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postmenstrual age, neonates possess 
almost complete hepatic capacity of 
tramadol metabolism to M1; however, 
compared to mothers, the renal eli-
mination of M1 is notably prolonged. 
(8,9) Despite its use in the treatment of 
labour pain for over a decade, there is 
no report, to our knowledge, of a fatal 
event with such use.
This case report suggests a probable 
association between fatal respiratory 
depression in a neonate and antenatal 
administration of tramadol in the mot-
her for labour pain.
Case report
For the 28 year old female this was her 
third pregnancy. Four weeks before 
delivery (in the 36th week of gestation) 
she had successful external cephalic 
version. Finally, labour was induced 
with oxytocin in the 40th week, at 10.30, 
because of 2 hours of  decelerations on 
cardiotocography. At 13.50 the mother 
was given one suppository of 100 mg 
tramadol hydrochloride (Tadol®, Krka, 
d.d., Novo mesto, Slovenia) and one 
suppository of 10 mg hyoscine butylbro-
mide (Buscopan®, Boehringer Ingelhe-
im International GmBH, Ingelheim am 
Rhein, Germany) for labour pain.
At 15.16 a boy (2910 g) was born with 
an APGAR score of 8 and 9 at 1 and 
5 minutes after birth, respectively. The 
baby stayed with his mother, but at 
16.50 he was found pulseless and 
apnoeic. He was cyanotic and hypo-
tonic. The physicians started cardio-
pulmonary resuscitation and 0.2 mg 
of adrenaline was delivered through 
an endotracheal tube. After 2 minutes 
heart rate was re-established.
At the arrival of the transport team, the 
newborn was already intubated and 
ventilated by the attending physician. 
His pulse rate was over 100 per minu-
te, blood pressure was 89/51 mmHg 
(left arm) and 86/55 mmHg (left leg). 
He was floppy, not reacting to any sti-
muli. His pupils were constricted and 
not reacting to light. The newborn was 
transported to the Level III Neonatal and 
Paediatric Intensive Care Unit.
A brain ultrasound was performed by 
an experienced paediatric radiologist. 
The ultrasound revealed diffuse hypo-
echogenic areas and small hyperecho-
genic areas periventriculary. Induced 
hypothermia (core temperature was 
held between 32 and 34 ºC) for neuro-
protection and therapy with phenobar-
bital was started. The Electroencepha-
logram (EEG) was repeatedly (3 times) 
abnormal and showed changes in acti-
vity, which were attributed to diffuse isc-
haemic lesions of the white substance. 
A neurologist confirmed the minimal 
status of consciousness of the newborn 
and no resuscitation was indicated. The 
child died 28 days after birth.
Blood samples were drawn from the 
mother at 5 h and from the newborn at 
7 and 72 h after birth. Tramadol con-
centration in the serum was determined 
using a gas chromatography–mass 
spectrometry (GC-MS) assay. The 
lower limit of quantification (LLOQ) of 
the method was 0.04 mg/l. Tramadol 
serum concentration in the mother was 
0.18 mg/l (therapeutic range 0.1-0.3 
mg/l). In the newborn, tramadol serum 
concentration at 7 h after birth was 0.05 
mg/l. A second measurement in the 
newborn, at 72 h was below the assay 
LLOQ.
Discussion
Labour pain inevitably affects maternal 
psychology, labour progress and foetal 
well-being. Consequently, adequate 
analgesia is essential in obstetrics. (10) 
Because of the lower incidence of side 
effects, and analgesic activity compa-
rable to pethidine, tramadol has been 
recommended for obstetrical analge-
sia. (6,11) Additionally, in the study by 
Khooshideh and Shahriari the duration 
of labour was shorter for the first stage 
(190 vs. 140 min) and for the second 
stage (33 vs. 25 min) in women treated 
with tramadol compared to pethidine. 
(11) In a previous study by Keskin et 
al., however, no difference with regard 
to the duration of labour and APGAR 
score was found, while superior anal-
gesic efficacy was observed in women 
treated with pethidine. (10) In general, 
tramadol is considered to have fewer 
cardiovascular, gastrointestinal and 
central depressant adverse effects than 
any other opioid drug. (2,3) The most 
common adverse effects observed with 
tramadol are: central nervous system 
(CNS) depression (27.4%), nausea and 
vomiting (21.1%), tachycardia (17.4%), 
seizures (13.7%), confusion (3.7%) and 
miosis (3.2%). (12) CNS depression can 
be successfully treated with naloxone 
and seizures with benzodiazepines. 
Dual mechanism of action and relatively 
slow metabolism of tramadol to M1 
result in prolonged analgesia. Con-
sequently, repeated doses of naloxone 
are necessary to antagonize the opi-
oid adverse effects. The influence of 
CYP2D6 polymorphism on tramadol 
pharmacokinetics has been extensively 
studied. However, its clinical importan-
ce regarding analgesic efficacy and 
safety has not been elucidated, espe-
cially in patients with UM phenotype. 
Based on the known mechanisms 
of action and the identified effects of 
CYP2D6 genotype on drug exposure, 
increased incidence of serotonergic 
effects is expected in patients with 
PM phenotype, while opioid mediated 
adverse effects are more likely in pati-
ents with UM phenotype. Tramadol and 
M1 have a high placental permeability 
and are not lost during foetal passage. 
In neonates, renal elimination of M1 is 
considerably prolonged, especially in 
the first hours post-partum. (8) Based 
on data by Stamer et al., the plasma 
concentrations of M1 in adult patients 
with UM phenotype is increased by 
more than 100%, compared to EM phe-
notype. (13) The exposure of the neo-
nate to M1, however, is hard to predict 
as it also depends on the time interval 
between drug administration and deli-
very of the child. While most people 
have EM phenotype, approximately 
1% of people in Finland, Denmark (14) 
and Slovenia, (15) 2% in Germany, (16) 
3.5% in Spain, (16) 10% in Greece and 
Portugal, (14) and 29% in Ethiopia (14) 
have CYP2D6 gene duplication resul-
ting in UM phenotype. 
The clinical signs presented in this case 
are consistent with opioid toxicity lea-
ding to respiratory depression and neo-
natal death. Furthermore, opioid indu-
ced respiratory depression may have 
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been enhanced by the anticholinergic 
action of hyoscine butylbromide. (17) 
According to the Naranjo probability 
scale, (18) respiratory depression was 
probably related to the tramadol trea-
tment (Q1 = 0; Q2 = 2; Q3 = 0; Q4 
= 0; Q5 = 2; Q6 = 0; Q7 = 0; Q8 = 
0; Q9 = 0; Q10 = 1, total score = 5). 
The measured serum concentration of 
tramadol in the mother at 6.5 h after 
administration of tramadol suppository 
was within the therapeutic range and 
consistent with the mean observed tra-
madol concentration with this type of 
administration (approximately 0.2 mg/l). 
(19) However, it is the formation of M1, 
which is probably related to the obser-
ved respiratory depression in the neo-
nate. Unfortunately, M1 concentration 
was not available, since this metabolite 
is not routinely measured in our toxico-
logy lab. Some pharmacokinetic data 
suggest that formation clearance of M1 
is a minor route in the total elimination of 
tramadol. (20,21) Consequently, genetic 
polymorphism of CYP2D6 has a more 
pronounced effect on the serum con-
centration time course of M1 than the 
concentration time course of tramadol. 
This is also supported by the study of 
tramadol pharmacokinetics in mothers 
treated for labour pain and their neona-
tes, where the serum concentration of 
tramadol in neonates at the time of birth 
was much less variable (range 0.122-
0.557 mg/l) then the serum concentra-
tion of M1 (range 0.003-0.112 mg/l). 
(8) Based on these data we speculate 
that in the presented case, the mother 
has a UM phenotype resulting in minor 
influence on the exposure to tramadol, 
but considerably increased exposure to 
M1. At the time of delivery, serum con-
centrations of M1 in the mother and the 
child were presumably near maximum. 
Due to immature renal function in the 
neonate, elimination of M1 from the child 
was prolonged, resulting in substantial 
increase in exposure of the child to M1. 
Again the tramadol concentration in the 
serum samples taken from the child did 
not deviate from previously reported in 
a group of neonates. (8) Furthermore, 
in the study by Claahsen-van der Grin-
ten et al., no relationship between the 
concentration of tramadol and M1 in 
the serum of the neonate and APGAR 
score 1 min post-partum was detected, 
in concordance with the present case 
of the child with APGAR score 8/9. (8) 
At the top of the body system ranking 
of adverse events in neonates was the 
respiratory system (14.3%); the inciden-
ce was not related to the tramadol dose. 
(8) The possible relationship with the 
concentration of tramadol or M1 was 
not commented. However, the authors 
report the case of respiratory depre-
ssion in a child probably related to the 
treatment with the highest concentration 
of tramadol (0.557 mg/l) and M1 (0.112 
mg/l). The respiratory status in this child 
immediately improved with naloxone 
treatment. (8) In our case naloxone was 
not used, since association of respira-
tory depression with tramadol use in 
the mother was not immediately reco-
gnized. Our hypothesis that neonatal 
death could be associated with the UM 
phenotype of the mother is further sup-
ported by a published case report of 
respiratory depression associated with 
elevated levels of M1 in an adult pati-
ent with renal impairment and CYP2D6 
gene duplication who was treated with 
tramadol. (22) Similar to the situation in 
newborns, elimination of M1 is prolon-
ged in patients with renal impairment. 
To confirm our hypothesis plasma con-
centration of M1 should have been mea-
sured and CYP2D6 genotype of the mot-
her should have been identified. Never-
theless, in mothers treated for labour 
pain, tramadol should be administered 
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